247 related articles for article (PubMed ID: 21083021)
21. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
[TBL] [Abstract][Full Text] [Related]
22. [Molecular international prognostic scoring system for myelodysplastic syndromes].
Nagata Y
Rinsho Ketsueki; 2023; 64(5):355-368. PubMed ID: 37271526
[TBL] [Abstract][Full Text] [Related]
23. [Myelodysplastic syndromes--new treatment options].
Germing U
Med Klin (Munich); 2006 Mar; 101 Suppl 1():123-6. PubMed ID: 16802536
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Cancer Genet Cytogenet; 2010 Jan; 196(2):159-66. PubMed ID: 20082852
[TBL] [Abstract][Full Text] [Related]
25. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.
Aul C; Giagounidis A; Heinsch M; Germing U; Ganser A
Rev Clin Exp Hematol; 2004 Dec; 8(2):E1. PubMed ID: 16027099
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors and risk models in myelodysplastic syndromes.
Komrokji RS; Padron E; Lancet JE; List AF
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S295-9. PubMed ID: 24290214
[TBL] [Abstract][Full Text] [Related]
27. Prognostic models in myelodysplastic syndromes.
Bejar R
Hematology Am Soc Hematol Educ Program; 2013; 2013():504-10. PubMed ID: 24319225
[TBL] [Abstract][Full Text] [Related]
28. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
[TBL] [Abstract][Full Text] [Related]
29. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study.
Chun K; Hagemeijer A; Iqbal A; Slovak ML
Leuk Res; 2010 Feb; 34(2):160-5. PubMed ID: 19665225
[TBL] [Abstract][Full Text] [Related]
30. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes.
Gondek LP; Haddad AS; O'Keefe CL; Tiu R; Wlodarski MW; Sekeres MA; Theil KS; Maciejewski JP
Exp Hematol; 2007 Nov; 35(11):1728-38. PubMed ID: 17920760
[TBL] [Abstract][Full Text] [Related]
31. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia.
Trost D; Hildebrandt B; Beier M; Müller N; Germing U; Royer-Pokora B
Cancer Genet Cytogenet; 2006 Feb; 165(1):51-63. PubMed ID: 16490597
[TBL] [Abstract][Full Text] [Related]
32. The cytogenetics of myelodysplastic syndromes.
Olney HJ; Le Beau MM
Best Pract Res Clin Haematol; 2001 Sep; 14(3):479-95. PubMed ID: 11640866
[TBL] [Abstract][Full Text] [Related]
33. The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes.
Nybakken GE; Bagg A
J Mol Diagn; 2014 Mar; 16(2):145-58. PubMed ID: 24457119
[TBL] [Abstract][Full Text] [Related]
34. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
35. The myelodysplastic syndromes: classification and prognosis.
Komrokji R; Bennett JM
Curr Hematol Rep; 2003 May; 2(3):179-85. PubMed ID: 12901338
[TBL] [Abstract][Full Text] [Related]
36. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
Bacher U; Haferlach T; Kern W; Weiss T; Schnittger S; Haferlach C
Cancer; 2009 Oct; 115(19):4524-32. PubMed ID: 19569249
[TBL] [Abstract][Full Text] [Related]
37. Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Giardini I; Rocca B; Zappatore R; Dambruoso I; Calvello C; Caresana M; Lazzarino M
Ann Hematol; 2010 Jun; 89(6):545-51. PubMed ID: 20217086
[TBL] [Abstract][Full Text] [Related]
38. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes.
Schiffer CA
Semin Hematol; 2008 Jan; 45(1):3-7. PubMed ID: 18179963
[TBL] [Abstract][Full Text] [Related]
39. Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes.
Wang H; Wang X; Xu X; Lin G
Ann Hematol; 2010 Jul; 89(7):671-9. PubMed ID: 20179929
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of cytogenetics in myelodysplastic syndromes.
Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
